Werewolf Therapeutics, Inc.
HOWL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $12 | $13 | $13 | $16 |
| G&A Expenses | $4 | $4 | $5 | $5 |
| SG&A Expenses | $4 | $4 | $5 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | $0 |
| Operating Expenses | $16 | $17 | $18 | $20 |
| Operating Income | -$16 | -$18 | -$18 | -$20 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$16 | -$18 | -$18 | -$20 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$16 | -$18 | -$18 | -$20 |
| % Margin | – | – | – | – |
| EPS | -0.36 | -0.4 | -0.4 | -0.46 |
| % Growth | 10% | 0% | 13% | – |
| EPS Diluted | -0.36 | -0.4 | -0.4 | -0.46 |
| Weighted Avg Shares Out | 45 | 45 | 45 | 44 |
| Weighted Avg Shares Out Dil | 46 | 45 | 45 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$15 | -$16 | -$16 | -$19 |
| % Margin | – | – | – | – |